Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Net Income towards Common Stockholders (2020 - 2025)

Historic Net Income towards Common Stockholders for Bioventus (BVS) over the last 5 years, with Q3 2025 value amounting to $4.0 million.

  • Bioventus' Net Income towards Common Stockholders changed N/A to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year change of. This contributed to the annual value of -$74.4 million for FY2023, which is 827.61% down from last year.
  • As of Q3 2025, Bioventus' Net Income towards Common Stockholders stood at $4.0 million.
  • In the past 5 years, Bioventus' Net Income towards Common Stockholders ranged from a high of $24.5 million in Q2 2021 and a low of -$74.4 million during Q2 2023
  • For the 4-year period, Bioventus' Net Income towards Common Stockholders averaged around -$10.1 million, with its median value being -$1.3 million (2021).
  • As far as peak fluctuations go, Bioventus' Net Income towards Common Stockholders surged by 13391.19% in 2021, and later crashed by 9348400.0% in 2022.
  • Quarter analysis of 4 years shows Bioventus' Net Income towards Common Stockholders stood at -$25000.0 in 2021, then plummeted by 93484.0% to -$23.4 million in 2022, then plummeted by 218.13% to -$74.4 million in 2023, then surged by 105.38% to $4.0 million in 2025.
  • Its Net Income towards Common Stockholders stands at $4.0 million for Q3 2025, versus $9.3 million for Q2 2025 and -$3.3 million for Q1 2025.